A study has shown that Celecoxib ( Celebrex ) and other anti-inflammatory coxib medications may counter the positive effects of Acetylsalicylic acid ( Aspirin ) in preventing blood clots.
The research, published in the Proceedings of the National Academy of Sciences ( PNAS ), has indicated that people who are taking Acetylsalicylic acid and coxibs together are in fact inhibiting the Aspirin's effectiveness in preventing myocardial infarctions and strokes.
This finding strongly suggests that humans who are consuming coxibs and a low dose of Acetylsalicylic acid simultaneously are exposed to a greater risk of cardiovascular events.
In the past decade, a new group of anti-inflammatory drugs, coxibs, which include Vioxx ( Rofecoxib ), Celebrex and Arcoxia ( Etoricoxib ) was developed to treat arthritis as well as other pain. Arthritis patients who take Celecoxib are instructed to take low-dose Aspirin to counteract Celecoxib's own potential clot-promoting effect.
Aspirin is the oldest and one of the most effective non steroidal anti-inflammatory drugs. It is also well known for its ability to prevent the blood clots that can potentially lead to myocardial infarction and stroke. Therefore, physicians often advise patients who are more prone to heart-related illnesses to take a daily tablet of low dose Aspirin ( 81 mg ). Approximately, 50 million Americans take Aspirin every day to reduce their risk of cardiovascular diseases.
Now, a new research suggests that in the presence of coxibs, Aspirin's protective role in preventing new blood clots is blunted.
This finding mirrors a cooperative study conducted at the University of Michigan, Ann Arbor, that showed for the first time that Celecoxib and other coxibs directly interfere with the protective qualities of Acetylsalicylic acid.
Source: Ben-Gurion University of the Negev, 2009